Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
91 hedge funds and large institutions have $214M invested in Concert Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
22% more capital invested
Capital invested by funds: $175M → $214M (+$38.7M)
15% more funds holding
Funds holding: 79 → 91 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SW
SVB Wealth
Boston,
Massachusetts
|
+$3.66M |
| 2 |
EP
Eversept Partners
New York
|
+$2.23M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.77M |
| 4 |
Millennium Management
New York
|
+$1.04M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$784K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
-$707K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$692K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$510K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$415K |
CNCE Hedge Fund Activity: Q2 2020 in Review
91 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2020, worth a combined $214M — up 22% from $175M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CNCE positions and 10 closed out — a net gain of 12 holders — while 32 added to existing stakes and 25 trimmed.
The largest buyer was SVB Wealth, opening a new position worth an estimated $3.66M. The largest seller was Sphera Funds Management, cutting an estimated $3M.
- 91 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2020, up from 79 in Q1 2020.
- Funds reported $214M of Concert Pharmaceuticals, Inc. stock for Q2 2020, up 22% quarter-over-quarter.
- 22 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2020 and 10 closed out, a net change of +12 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2020 was SVB Wealth, an estimated $3.66M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2020 was Sphera Funds Management, an estimated $3M sold.
Based on aggregated 13F filings for Q2 2020.